Keratinocytes comprise the majority of cells in the epidermis, the interleukin-1 rich layer of tissue contiguous with the outside world. Keratinocytes produce IL-la and , ( mRNA in vitro, but only IL-la biological activity has been identified in keratinocyte cultures. In contrast, monocytes secrete biological activities attributable to both species of IL-1. Using several monoclonal antibodies to IL-1,6, significant amounts of IL-1l8 protein could be found in keratinocyte cultures; all of this immunoreactive IL-1lB was in the 31-kD form. This latent cytokine has been shown to bind inefficiently to the IL-1 receptor and to be (in relative terms) biologically inactive. Chymotrypsin cleaves 31-kD IL-1l8 at Tyr 113-Val 114, generating an 18-kD IL-1 species with activity equivalent to the authentic mature IL-1,8 (NH2-terminal Ala 117). Treatment of 31-kD keratinocyte IL-13 with chymotrypsin also generated an 18-kD molecule and significant IL-1 activity. Monocytes contain an IL-1 convertase enzyme that cleaves the IL-1l8 promolecule at Ala 117. We demonstrate here that keratinocytes do not contain such an IL-1 convertase activity, nor do they contain any activity capable of productively processing 31-kD IL-1lB into a biologically active form. These data suggest that keratinocytes (and other non-bone marrow-derived cells) produce IL-1l8 in an inactive form that can be processed only after leaving the cell. (J. Clin.
Introduction
The recent observation that nearly every cell type examined can produce interleukin 1 a and/or ( mRNA in vitro after appropriate induction (1, 2) has forced a reevaluation of the role of IL-1 in immune and inflammatory processes. A complicating factor is the observation that the detection ofmRNA for an IL-1 species does not necessarily indicate that a biologically active protein is being produced (I1-4). In this study, we address this phenomenon and the paradox of IL-1 production by human epidermal keratinocytes. Keratinocytes contain mRNAs identical to monocyte and (3 mRNA (4) (5) (6) , and these mRNAs can be induced to accumulate by various stimuli (7, 8) . While these cells synthesize significant amounts of IL-1 a protein that is biologically active, we and others have been unable to demonstrate biological activity attributable to IL-1(3 (4, 9, 10) . In addition, we and others have found that the prodigious amount of IL-1 activity in normal epidermis is exclusively due to IL-1 a (10, 1 1) . In this study, we demonstrate that keratinocytes translate IL-13 pro-mRNA into protein and contain significant amounts of 31 -kD IL-1, 8 . Furthermore, we show that keratinocytes, unlike monocytes, lack enzymatic activity capable of generating mature 1 7-kD IL-1(, from the precursor molecule. We found that keratinocyte pro-IL-1, can be converted in vitro to a biologically active molecule by exogenous proteases. The significant differences between keratinocytes and monocytes with regard to IL-1 production and processing are discussed in terms of the discrete role ofeach cell in host defense. This is the first clear demonstration that natural 3 1-kD pro-IL-1,B lacks significant biological activity until proteolytically processed, and raises important analogies between pro-IL-1(3 and other latent cytokines.
Methods
Keratinocytes. Normal human keratinocytes from foreskin or from patients undergoing reconstructive surgery were obtained as described previously (4, 12) or purchased from Clonetics Corp. (San Diego, CA) and grown in MCDB 153 medium supplemented as described by Boyce and Ham (13) . Cells grown in MCDB 153 were trypsinized and replated on tissue culture plastic before primary cultures reached confluence, and these secondary or tertiary cultures were used for all subsequent studies. Interleukin 1. Recombinant "mature" or 1 7-kD human IL-1# encoded by the latter half of the IL-1,8 cDNA (codons 117-269) was synthesized in a prokaryotic expression vector under control of a temperature sensitive repressor (14) . The protein was extracted from Escherichia coli and purified to apparent homogeneity by sequential sulfopropyl sephadex, DEAE, and Procion Red column chromatography (Bethesda Research Laboratories, Gaithersburg, MD) as described (14) . Minor modifications ofa similar protocol were used to obtain the 17-kD form of IL-la. Expression of recombinant "precursor", 31-kD, or "pro-IL-I fl" involved the use of a full length (codons 1-269) IL-D 1 cDNA using the same temperature sensitive repressor (15). After lysis of bacteria, 3 1-kD IL-1,B was purified using sequential Q Sepahrose, Procion Red, and Phenyl-Sepharose CL-4B chromatography as previously described (15).
Anti IL-I antibodies. Monoclonal anti-IL-I antibodies for immunoblotting (anti-IL-lBf M1, M2, M3, and M4, and anti IL-Ia M5) have been previously described (15). Anti-IL-l,B monoclonal antibodies for immunoblotting and for ELISA (ANOC 243 and ANOC 205) were also provided by Otsuka Pharmaceutical Co. (Tokushima, Japan). IL-la and IL-l# immunoaffinity gels were provided by Endogen (Boston, MA) and were used according to manufacturer's instructions. Briefly, for removal ofIL-1 a from the keratinocyte lysate, gels were washed five times with PBS and mixed with NHK lysate. The mixture was incubated and gently mixed for 1 h at 37°C, centrifuged, and the IL-la supernatant was recovered for further experiments.
IL-I biological assay. The assay to detect IL-I activity utilizes the T cell clone DIO.G4.1 and the clonotype-specific monoclonal antibody 3D3 and has been described in detail (16, 17 IL-I ELISA. The IL-la ELISA kit was provided by Endogen. The IL-1I1 ELISA kit was provided by Otsuka Pharmaceutical Co. Assays were done according to manufacturer's instructions. Briefly, purified antibodies were coated on microtiter plates overnight at room temperature. After the plates were blocked by bovine albumin solution for 4 h and washed and soaked in 0.05% Tween 20 PBS, samples and serial dilutions of recombinant human IL-I (rhIL-I) were added and left at 4°C overnight. After washing, purified anti-IL-1 rabbit serum was added for 2 h and washed again. Goat anti-rabbit IgG antibodies coupled to peroxidase were added for an additional 2 h and peroxidase activity was developed by using H202-ortho-phenylenediamine substrate.
Immunoblotting. Samples (affinity purified or freshly isolated keratinocyte lysate) were loaded on to a 13% polyacrylamide gel containing 0.1% SDS under reducing or nonreducing conditions. After electrophoresis, proteins were transferred onto nitrocellulose membrane (BioRad Laboratories, Richmond, CA) in a trans-blot cell apparatus (BioRad Laboratories). The blot was blocked with dry milk and then incubated for 1 h with monoclonal anti-IL-I antibody (see above) diluted in 0.05% Tween 20 10 mM Tris-buffer (ph 8.0) (TBST). After washing in TBST, alkaline phosphatase-conjugated goat anti-mouse IgG antibody (Promega Biotec, Madison, WI) was added and the blot was developed and photographed.
Results
Conditioned medium from keratinocytes grown under conditions that inhibit or promote differentiation do not contain sufficient IL-I to measure in either the IL-I a or 13 ELISA system (not shown). These results are consistent with the observation that under most conditions, the vast majority of IL-1 present in keratinocyte cultures is cell associated (7) . Sonicated lysates of keratinocytes were tested for IL-1 a and 1 in the appropriate ELISA. Results are shown in Fig. 1 between groups after 48 h of culture in the above conditions. step) antibody in an ELISA kit obtained from Otsuka Pharmaceutical Co., showed that the monoclonal antibody clearly recognizes both species, indicating that the IL-I1 ELISA should detect both mature and pro-IL-1(3 (not shown).
The molecular weight of cell-associated IL-1 was determined by Western blotting. Lysates of keratinocytes were electrophoresed under reducing and nonreducing conditions and analyzed using monoclonal antibodies to either IL-1 a or IL-11. Under nonreducing conditions, mature rIL-113 often appeared in a dimeric form. This occurred minimally (or not at all) when gels were run under reducing conditions, regardless of the antibody used for Western blotting. Keratinocyte lysate material immunoreactive with IL-l1( antibodies migrated in a fashion similar to pro-IL-13 at 31 kD. No immunoreactivity was seen in the range of 17 kD, where the majority of recombinant mature IL-1(3 migrates. A similar pattern was seen using monoclonal antibodies directed at different epitopes on the IL-13 molecule, suggesting that these immunoreactive bands represented authentic IL-1 (Fig. 2 , A-C). This was true for all antibodies under reducing and nonreducing conditions. That this occurred even after cell lysis suggested that minimal proteolytic activity for pro-IL-113 exists in keratinocytes, and that cell-associated IL-113 exists as a pro-molecule in keratinocytes. IL-1 a antibodies also detected a 3 l-kD species (consistent with our previous results, as described in reference 8) (Fig. 3) . It should be noted that previous reports have suggested the pro-and mature IL-1 a and mature IL-113 have comparable IL-1 bioactivity, while pro-IL-113 has little if any activity ( 15, 18) .
The results of the Western blotting experiments suggested that the explanation for the lack of IL-113 biological activity in keratinocyte cultures was the existence of IL-11 exclusively in a precursor form. If true, we reasoned that we should be able to generate a lower molecular weight IL- 11 with enhanced biological activity by treating keratinocyte lysates with an appropriate protease. As an initial approach, we treated recombinant pro-IL-l3 with alpha-chymotrypsin, a protease previously shown to cleave recombinant pro-IL-113 at Tyr 11 3-Val 114 (15). Fig. 4 indicates that this manuever generates an immunoreactive band which migrates slightly higher than mature recombinant IL-11, consistent with a molecule three amino acids longer than mature IL-113. Fig. 5 demonstrates that in the D10 assay, chymotrypsin itself has no activity. At 160 pg/ml, recombinant pro-IL-113 has no significant activity in this assay either, consistent with previous reports (15, 18). However, the addition of chymotrypsin to recombinant pro-IL-113 generates significant activity in the D1O assay, comparable to similar amounts of mature IL-la (column 4) or mature IL-1,8 (not shown). These experiments confirmed that pro-IL-11 had little biological activity, but indicate that its chymotrypic digest has significant biological activity.
In the next series of experiments, keratinocyte lysates were treated with chymotrypsin in parallel with recombinant pro-IL-113, and the digests were analyzed by Western blotting. To demonstrate that chymotryptic digestion of keratinocyte lysates generated a biologically active IL-11, it was first necessary to remove the IL-I a from these lysates. This was accomplished using an immunoaffinity agarose gel coupled to IL-I a antibodies (Endogen) (see Methods). Fig. 7 demonstrates that while keratinocyte (NHK) lysates contain significant IL-I activity, incubation with the affinity gel specific for IL-a led to a virtually complete abrogation of this activity. The efficacy of this gel in the removal of IL-I a was confirmed by ELISA (not shown). This result confirmed previous reports that IL-I biological activity in keratinocyte cultures is attributable to IL-1 a (4, 10, 11). This IL-la-depleted keratinocyte lysate was then treated with chymotrypsin under conditions identical to those used for the experiment shown in Fig. 6 . Chymotrypsin treatment generated significant activity in the D 10 assay, and treatment of a mock IL-a-depleted lysate with chymotrypsin also led to a significant increase in the amount of IL-I activity. The activity in both lysates could be substantially blocked with antibodies to IL-1,8 (not shown).
Since keratinocyte pro-IL-113 was susceptible to proteolytic cleavage by exogenous proteases, and since this proteolytic digestion led to the generation ofbiological activity, these experiments suggested an intrinsic absence of specific protease activity for pro-IL-I1B in keratinocytes. In contrast, monocytes contain a coinducible protease that can cleave pro-IL-I at ala 1 17. Fig. 8 
Discussion
Upon stimulation in vitro, monocytes produce significant amounts of IL-1 a and mRNA and protein, and convert pro-IL-13 to a mature biologically active species using at least one distinct protease (1, 2, (19) (20) (21) 24) . A significant amount ofboth immature and mature IL-11 is secreted from the cell in a poorly understood fashion (24, 25) , while the majority ofIL-a remains in a cell-associated compartment (23, 24, 26, 27) . In direct contrast, cultured fibroblasts do not express IL-a mRNA and express IL-13 mRNA only after exogenous stimulation (3) . Further signals are required for the translation of this mRNA (3), and the pro-IL-1l thus produced has not been shown to be converted to a mature molecule (3, 22, 23) . This study suggests the basis of a third strategy of IL-1 production that is exhibited by the cultured keratinocyte that produces significant biologically active IL-a protein but does not produce biologically active IL-113 protein.
We have demonstrated that despite the lack of biological activity attributable to IL-13, cultured keratinocytes contain significant amounts of a protein that is identical to pro-IL-113 by several criteria. First, keratinocyte pro-IL-l11 comigrates with recombinant pro-IL-l,B, and can be detected by ELISA and Western blot analysis using several monoclonal antibodies directed at different epitopes on the IL-113 molecule. Second, the chymotryptic digest of keratinocyte IL-1 comigrates with the chymotryptic digest of recombinant pro-IL-113, and in both digests a band which migrates slightly higher than authentic mature IL-113 can be demonstrated. Finally, while neither ILla-depleted keratinocyte lysate nor recombinant pro-ILhave significant activity in IL-1 bioassays, their chymotryptic digests contain substantial biological activity.
It is of interest that even if keratinocyte lysates were generated under conditions where no protease inhibitors were included in the mixture, lysates contained no IL-11 species that migrated below 31 kD. In contrast, monocytes prepared in this fashion show significant amounts of mature 1 7-kD IL-113 (see Fig. 8 ). While this observation suggested a lack ofIL-113 convertase activity, this was confirmed by the lack of processing of recombinant pro-IL-11 when it was mixed with keratinocyte lysates. Parallel lysates of monocytes contained significant ILconvertase activity. The absence of convertase activity in keratinocytes is consistent with a similar absence of such activity in various fibroblast lines (20) .
Why do cells which cannot process pro-IL-113 into a biologically active species expend the energy to produce it? Several possibilities exist. First, pro-IL-l,B may have an intracellular role which is independent of its capacity to bind to the cell surface IL-I receptor. For example, reports that IL-1 , is myristoylated, and evidence that myristoyl proteins perform important intracellular functions (27) , suggest that this is at least a hypothetical role for intracellular IL-113. Second, it may be that the failure of us and others to detect processing of pro-IL-113 is an artifact ofin vitro culture systems. Finally (and the interpretation we favor), IL-I1 produced by cells such as fibroblasts and keratinocytes may serve as a potential substrate for extracellular proteases after cell injury or death. Specifically, pro-IL-113 released by injured or dying cells could be converted to active IL-1,B in the extracellular space by inflammatory cell proteases, thus activating uninjured resident cells to produce IL-1-inducible cytokines, which attract and activate cells ofthe immune and inflammatory systems, e.g., IL-6, IL-8, granulocyte-macrophage (GM)-CSF, and G-CSF (9). That many ofthe stimuli which induce IL-13 gene expression are injurious (1, 2, 7) is also consistent with this paradigm.
Keratinocytes are unique in that terminally differentiated cells are "excreted" by desquamation, and thus in the absence of injury their contents do not come in contact with the internal milieu of the body. Therefore, if IL-la produced by the keratinocyte in vivo remains in a cell-associated compartment, it is "excreted" with the cell if unused. IL-1 a, which is present in prodigious amounts (in biological terms) in normal epidermis (9-1 1) and does not require proteolytic processing to manifest biological activity, is thus well suited to its epidermal location. Traumatic injury to the skin releases IL-la, which has immediate effects on contiguous keratinocytes, fibroblasts, and endothelial cells relevant to inflammation and wound healing (9, 1 1). Thus, there is no absolute requirement for the presence of inflammatory cells and their proteases to initiate the generation of IL-I bioactivity in the injured cutaneous microenvironment. IL-113 produced by keratinocytes, however, must be activated by the products ofsuch inflammatory cells; alternatively, activation of other nonepithelial cells resident to epidermis may lead to protease production. It should be noted that lower molecular weight forms of IL-1# can be identified in psoriatic epidermis (10) . The absence of biological activity attributable to IL-1I in psoriatic epidermal samples suggests that nonproductive cleavage of pro-IL-1I does occur in this setting.
There is an accummulating body of evidence that several pleiotropic cytokines require proteolytic processing for the generation of biological activity. TGF beta is secreted in an inactive form by most cells (28, 29) , and requires proteolytic processing for its multiple activities to become manifest (28, 29) . Similarly, TNFc/cachectin may be produced as a promolecule with negligible biological activity that requires proteolytic processing to manifest activity (30) . That keratinocytes contain both TGF,B and TNFa/cachectin mRNA but often lack concordant biological activity attributable to these cytokines (unpublished observation) suggests that keratinocytes may lack these requisite proteases as well.
Recently, it was demonstrated that coculture ofendothelial cells and pericytes (but not endothelial cells alone) led to the generation of active TGF 13 (31) , suggesting that certain cellcell interactions may activate latent cytokines. It is at present unknown whether coculture of IL-IB-producing cells (notably keratinocytes) with cells capable of processing IL-1# yield biologically active IL-1, though preliminary evidence suggests that melanocytes possess IL-I convertase activity. With our report, it would appear that activation of latent cytokines such as IL-13 by specific proteases may be an important level ofregulation for the generation of cytokine biological activities.
